DUBLIN – AC Immune SA could receive up to $509 million in up-front and milestone payments in a licensing deal with the Janssen Pharmaceuticals arm of Johnson & Johnson involving its first-in-class tau-targeting vaccine ACI-35, which is in clinical development for Alzheimer's disease (AD).